ABSTRACT
INTRODUCTION
Lung cancer has a high mortality rate, 1 which is related to the fact that the majority of patients present with advanced stage at time of diagnosis. The mean 5-year survival is <15%, 2, 3 while for stage IA lung cancer the 5-year survival rate is approximately 65%. 4 Sputum cytology is occasionally part of the diagnostic investigation of lung cancer. Prolonged sputum collection leads to more adequate sputum for cytological assessment, regardless of method of sputum collection. 5, 6 Procurement of sputum, which can be self-collected in a non-invasive manner, is inexpensive and simple.
It is assumed that tumours shed cellular components such as free DNA, as well as dead cells in in the bronchial epithelial lining fluid. 7 Highly sensitive molecular techniques applied on sputum are capable of detecting molecular tumour-related DNA alterations, such as mutations in KRAS and p53, [8] [9] [10] and DNA methylation. 9, [11] [12] [13] [14] [15] [16] [17] Hypermethylation of the promoter of tumour suppressor genes results in gene silencing 18, 19 and is considered to be a major event in the initiation and progression of lung cancer. In previous reports, promoter hypermethylation of tumour suppressor genes RASSF1A, adenomatous polyposis coli (APC) and cytoglobin (CYGB) have been identified as potential biomarkers for lung cancer detection in sputum. [11] [12] [13] 16, [20] [21] [22] [23] The aim of this methodological study was to investigate the sensitivity for molecular lung cancer diagnosis by prolonged sputum sampling. To this end, sputum samples were collected during nine consecutive days in three canisters I, II and III (i.e., days 1-3, days 4-6, days 7-9, respectively) in both lung cancer patients and cancer-free controls, in which we examined gene promoter hypermethylation.
METHODS

Subjects
Prospective sputum samples were collected by patients diagnosed with lung cancer and patients with chronic obstructive pulmonary disease (COPD) as controls who have been enrolled in an on-going lung cancer screening study in the region of Amsterdam,
The Netherlands. For this study, in a consecutive series, we selected the first 53 lung cancer patients and 47 controls who collected sputum over a period of nine successive days and had a positive control PCR (see below). The study protocol was approved by the Institutional Review Boards of participating hospitals and all subjects provided written informed consent. Lung cancer patients were considered eligible for inclusion in the study when they were diagnosed with lung cancer prior to treatment, or when progressive disease was evident after treatment. In the control group, individuals with spontaneous sputum production and no history of lung cancer in the past 3 years were included. Controls diagnosed with COPD were classified according to the Global Initiative for Chronic Obstructive Lung
Disease criteria. 24 Clinicopathological data were retrieved from medical records after a follow-up period of at least 1 year after enrolment in this study.
Sputum collection
Sputum was collected in Saccomanno's fixative (2% polyethylene glycol in 50% ethanol) as described before 25 with slight modification: patients were requested to collect spontaneous (non-induced) sputum at home on nine consecutive days, preferably in the morning, using three canisters in such a way that each single canister contained sputum expectorated during a period of three successive days. Canister I represented days 1-3, canister II days 4-6 and canister III days 7-9. After 9 days of sputum collection, the batch was returned to the VU University Medical Center Amsterdam. In lung cancer patients, sputum was sampled at time of cancer diagnosis, before cancer treatment or after recurrence. Ct values of more than 40 were considered to represent a non-methylated test result.
All samples had Ct values below 27 for MYOD1, which indicates good DNA quality and recovery after bisulphite treatment. Samples were tested in duplicate and displayed good reproducibility. To relate the effect of cumulative testing of canisters I, II and III to repetitive (triplicate) testing on one canister, the multiplex assay was performed thrice 
on one of the canisters (i.e., canister II).
Statistical analysis
As cut-off value for diagnostically relevant hypermethylation for a specific marker, we determined the 99th percentile of the methylation ratios of this marker in all canisters of controls. A sample was considered positive for promoter hypermethylation of the respective marker when its methylation ratio was equal to or above the cut-off. was considered significant.
After establishing presence of hypermethylation in canister I, the percentage and Canister I = days 1-3; II = days 4-6; III = days 7-9. a χ2 test P-value <0.001.
b χ2 test P-value <0.05. APC = adenomatous polyposis coli; CYGB = cytoglobin; qMSP = quantitative methylation-specific PCR.
RESULTS
Clinicopathological data of study participants are shown in Table 2 .
Promoter hypermethylation frequencies of RASSF1A, APC and CYGB genes stratified per canister (i.e., I, II, III) and case-control status are shown in Table 3 .
Cochran's Q test did not show statistically significant differences in frequency of hypermethylation for all three markers among canisters I, II and III, both in cancer patients and control subjects. Hypermethylation frequency of RASSF1A, CYGB and the combination of RASSF1A/CYGB/APC was significantly increased in cancer patients over controls in all canisters.
Cumulative 6-and 9-day methylation frequencies of RASSF1A, APC or CYGB showed that sensitivity of lung cancer detection increased (Table 4) .
Combined RASSF1A/APC/CYGB methylation analysis of sputum of canister I had a sensitivity of 43%, increasing to 53% when canister II is added and 64% when all three canisters were considered, with corresponding specificity of 96%, 94% and 91%, respectively.
To further explore the additive value of sampling sputum during more than 3 days, we determined the number of positive cases in the group who tested negative in canister I (Table 5) .
Of the 30 cases who tested negative for all three biomarkers in canister I, an additional 
DISCUSSION
This is the first study examining the influence of duration of sputum collection on sensitivity of gene promoter hypermethylation analysis for lung cancer. Here, we
show that Table cumulative 6-or 9-day methylation analysis substantially increases the chance of identifying lung cancer. Combined RASSF1A, APC or CYGB promoter methylation analysis demonstrated a sensitivity of 43% and specificity of 96% in sputum samples collected during three consecutive days, increasing to 64% (specificity 91%) for 9-day cumulative combined methylation analysis.
Our findings of improved sensitivity for lung cancer diagnosis when sputum is sampled over more than three consecutive days are in line with studies evaluating cytology in sputum specimens that were sequentially collected over several days.
5,26
The proportion of lung cancer diagnosis by means of sputum cytological examination was shown to increase with longer collection time. Apparently, the detection rate of aberrant tumour DNA and malignant cells may increase when sputum is investigated over a prolonged period of time.
Kennedy et al 6 have evaluated procedure of sputum collection on sputum adequacy by means of sputum cytology. Patients with COPD were randomised into two groups, the first to collect spontaneous sputum at home, followed by a single production of induced sputum at the hospital. The other group received the same instructions, but in reverse order. In both groups, the second sputum sample was demonstrated to provide best quality of sputum, irrespective of the sampling method. The authors concluded that in time a learning effect for sputum collection occurred in the patients which had a positive impact on the quality of the sputum for cytology reading.
Although we investigated epigenetic alterations instead of cytological aberrations, we found no differences in number of positive samples detected by gene promoter hypermethylation between the canisters. Some subjects scored negative in canister I but positive in canister II and vice versa, but overall, this made no difference on the general outcome of positive hypermethylation. A likely explanation for the difference with the study of Kennedy et al 6 is the detailed instructions on the patient sputum information sheet, and the verbal instruction at inclusion used in this study, which may have overcome the learning effect.
In this study, we investigated gene promoter hypermethylation of RASSF1A, CYGB and APC. These markers have shown to be useful as markers for early detection of lung cancer. RASSF1A, which encodes a protein similar to RAS effector proteins, is involved in apoptosis and signal transduction. 27, 28 RASSF1A is considered to be a tumourassociated biomarker. 21 RASSF1A is rarely hypermethylated in sputum of smokers, and more frequent hypermethylation is present in sputum of patients with invasive lung cancer. 16, 21, [29] [30] [31] [32] [33] CYGB is an emerging marker. 20 The function of this gene is not yet clear;
it is distantly related to myoglobin and proposed to play a role in sensing and transport of oxygen and collagen synthesis. [34] [35] [36] It is still unclear how CYGB is involved in cancer pathogenesis, although its silencing in lung cancer supports a putative tumoursuppressor function. In vitro, restoration of CYGB in cancer cell lines has been shown to inhibit cancer growth, whereas silencing resulted in increased colony formation. 20 Last, the APC gene is mostly known because of its crucial role in the development of colon cancer in the adenoma-carcinoma sequence. 37 APC is a Wnt-pathway antagonist and regulates, through transcriptional activation, cell migration and adhesion. In sputum of lung cancer patients and smokers, APC is reported to be hypermethylated.
In this study, results of RASSF1A (28%-30% in lung cancer patients) and CYGB promoter hypermethylation (17%-28% in lung cancer) are comparable with outcomes of previous studies, 11, 16, 20 while we found a lower frequency of APC promoter hypermethylation (6%-13%) compared with previous reports. 16, 23 In conclusion, sensitivity of gene promoter hypermethylation analysis in sputum for lung cancer increases when sputum is sampled during more than three consecutive days. This study suggests further research for establishing diagnostic performance of methylation markers on sputum samples of a larger cohort.
